Graph Therapeutics, a cutting-edge biotechnology startup, has successfully raised $3.25 million in pre-seed funding to accelerate the development of its innovative AI-driven platform for drug discovery. This investment marks a significant milestone in the company’s mission to tackle complex inflammatory diseases using advanced artificial intelligence and machine learning techniques.
This funding round was spearheaded by leading investors, including Squareone and Merantix Capital, alongside NAVEC Investment Management and strategic angel investors. Among these contributors is Mehdi Ghissassi, who participated through the Atomico Angel Program, underscoring the growing global confidence in AI as a transformative force in the biotech sector.
Graph Therapeutics is dedicated to addressing the urgent need for more effective treatments for inflammation and immunology (I&I) disorders. The I&I therapeutics market is projected to surpass $257 billion globally by 2032, signaling an immense opportunity to develop innovative therapies. With this funding, Graph Therapeutics is poised to revolutionize this market by leveraging a next-generation, lab-in-the-loop AI platform designed to streamline the drug discovery process.
The platform integrates ex vivo perturbation modeling, multimodal datasets, and advanced machine learning algorithms to identify clinically relevant drug targets with high precision. This unique combination enables researchers to bridge the gap between pre-clinical models and real-world patient outcomes, significantly reducing the time and cost associated with traditional drug development processes.
The founders of Graph Therapeutics—Dr. Gregory Vladimer, Dr. Berend Snijder, and Dr. Robert Sehlke—bring a wealth of expertise in precision oncology and immuno-oncology to the company. Dr. Vladimer, who serves as CEO, previously co-founded Allcyte, a precision medicine company acquired by Exscientia in 2021. Dr. Sehlke, the CTO, spearheaded computational platform development at Allcyte before joining Graph Therapeutics. Their combined experience has laid a strong foundation for Graph’s ambitious vision.
Graph Therapeutics’ immediate focus is on sterile inflammation, a condition characterized by an immune response without infection, which plays a pivotal role in various chronic and autoimmune diseases. By leveraging its AI platform, the company aims to develop therapies that rebalance the intricate networks of the immune system to treat these challenging conditions effectively.
Dr. Vladimer explained the company’s approach, stating, “Tackling immune-driven diseases requires a fundamentally different strategy. By combining advanced AI with primary patient disease models, we are uniquely positioned to address the complexities of immune dysregulation and bring impactful therapies to market.”
The $3.25 million investment will also support the expansion of Graph Therapeutics’ interdisciplinary team of computational biologists and data scientists. This will further refine their platform and establish strategic partnerships to drive the commercialization of their solutions.
As the biotech industry increasingly embraces AI to unlock new possibilities, Graph Therapeutics is emerging as a leader in using this technology to address unmet medical needs. With its groundbreaking approach to inflammatory disease treatment, the company is paving the way for more efficient, cost-effective, and patient-centric drug discovery, offering hope to millions worldwide.
Shein, the fast-fashion giant,...
The European tech landscape has...
Tune Therapeutics, a pioneering biotech...
No tags available for this post.
Leave a Reply